StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
CRISPR Therapeutics (CRSP) Reiterated at Market Outperform by Citizens on CTX310 Data
August 31, 2026 5:02 AM
Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $80.00 price target on CRISPR Therapeutics (NASDAQ: CRSP).The analyst commented ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
